NCT07089381View on ClinicalTrials.gov

Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.

NARecruitingINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

February 1, 2026

Study Completion Date

June 1, 2026

Conditions
Rheumatic ArthritisRheumatoid Arthritis (RA) PreventionInflamationAntioxidantAnti Oxidative StressAnti AgingC Reactive ProteinMethotrexateQuality of Life Outcomes
Interventions
DIETARY_SUPPLEMENT

Resveratrol 1 gm.

59 patients will receive the standard treatment for management of RA in addition to Resveratrol 1 gm daily, (Organix, Egypt) (given as one 1000 mg tablets once daily) for 3 months.

DRUG

Methotrexate

59 patients will receive the standard treatment for management of RA for 3 months

Trial Locations (1)

Unknown

RECRUITING

Department of Rheumatology at Ain Shams university hospital, Cairo, Egypt, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT07089381 - Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis. | Biotech Hunter | Biotech Hunter